Menopausal hormone therapy influence on breast cancer outcomes in the women's health initiative

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 7, 2015, Pages 917-924

  Chlebowski, Rowan T ^a   Aragaki, Aaron K ^b   Anderson, Garnet L ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BODY MASS; BREAST BIOPSY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SIZE; CLINICAL PRACTICE; FOLLOW UP; HUMAN; OBSERVATIONAL STUDY; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME; WOMEN'S HEALTH; BREAST NEOPLASMS; ESTROGEN THERAPY; FEMALE; INCIDENCE;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE;

EID: 84938055350     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0106     Document Type: Review

References (48)

1. Chlebowski RT, Anderson G. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012;104:1-11.
2. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-1167.
3. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-1170.
4. Hoover R, Gray LA Sr, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med 1976;295:401-405.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059.
6. Norman SA, Weber AL, Localio AR, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010;19:440-447.
7. Pocobelli G, Newcomb PA, Li CL, et al. Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. Breast Cancer Res Treat 2014;145:439-447.
8. Newcomb PA, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:864-871.
9. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.
10. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-881.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
13. Manson JA, Chlebowski RT, Stefanick ML, et al. The Women's Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases. JAMA 2013;310:1-17.
14. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative (WHI) randomized clinical trials. JAMA Oncol 2015;1:296-305.
15. Chlebowski RT, Hendrix SL, Langer RD, et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
16. Chlebowski RT, Anderson G, Gass M, et al. Influence of estrogen plus progestin on breast cancer incidence and mortality. JAMA 2010;304:1684-1692.
17. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection with mammography and breast biopsy. Arch Intern Med 2008;168:370-377.
18. Hou N, Hong S, Wang W, et al. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 2013;105:1365-1372.
19. Chlebowski RT, Anderson GL, Aragaki G, Prentice R. Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index. J Natl Cancer Inst, in press.
20. Beral V; Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003;362:419-427.
21. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
22. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2011;18:385-392.
23. Ravdin PM, Cronin KA, Howlander B, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674.
24. Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 2012;66:1-7.
25. Chlebowski RT, Kuller L, Prentice RL, et al. Breast cancer after estrogen plus progestin use in postmenopausal women. N Engl J Med 2009;360:573-587.
26. Santen RJ, Yue W, Heitjan DF. Occult breast tumor reservoir: biological properties and clinical significance. Horm Cancer 2013;4:195-207.
27. Joshi PA, Goodwin PJ, Khokha R. Progesterone exposure and breast cancer risk understanding the biological roots. JAMA Oncol 2015;1:283-285.
28. Chlebowski RT, Manson J, Anderson G, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative observational study. J Natl Cancer Inst 2013;105:526-535.
29. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: the Women's Health Initiative randomized trial. JAMA 2006;295:1647-1657.
30. Chlebowski RT, Anderson G, Manson J, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 2010;28:2690-2697.
31. Anderson GL, Chlebowski RT, Aragaki A, et al. Oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy extended follow-up of the Women's Health Initiative randomized trial. Lancet Oncol 2012;13:476-486.
32. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
33. Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145:535-543.
34. Cherry N, McNamee R, Heagerty A, et al. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year followup of the ESPRIT randomized controlled trial. BJOG 2014;121:700-705.
35. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409.
36. Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast conserving surgery. Lancet Oncol 2013;14:e348-357.
37. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 2015;149:569-575.
38. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236.
39. Eng A, Gallant Z, Shepherd J, et al. Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods. Breast Cancer Res 2014;16:439.
40. Luo J, Cochrane BB, Wactawski-Wende J, et al. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2013;137:915-925.
41. Rohan TE, Negassa A, Chlebowski RT, et al. Estrogen plus progestin and risk of benign proliferative breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2337-2343.
42. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008;100:563-571.
43. McTiernan A, Martin C, Peck J, et al. Estrogen and progestin influence on mammogram density in healthy postmenopausal women in the Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-1376.
44. McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial. J Clin Oncol 2009;27:6135-6143.
45. Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen alone Women's Health Initiative clinical trials. Breast Cancer Res Treat 2012;132:275-285.
46. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
47. Farhat GN, Parimi N, Chlebowski RT, et al. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013;105:1496-1503.
48. Zhao S, Chlebowski RT, Anderson GL, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res 2014;16:R30.